Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern
1. CagriSema shows substantial weight loss but adverse events raise concerns. 2. NVO stock dropped over 7% following trial results and market reactions. 3. CagriSema's trials indicate high efficacy for weight loss but safety issues remain. 4. Analysts express disappointment over CagriSema's differentiation from competitors. 5. Ongoing trials aim to explore more about CagriSema's potential.